Azopt (brinzolamide ophthalmic suspension) is a carbonic anhydrase inhibitor, which reduces the amount of fluid in the eye, used to treat certain types of glaucoma and other causes of high pressure inside the eye.
signs of infection (e.g., fever, chills, persistent sore throat), or
chest pain.
Dosage for Azopt
The recommended dose is one drop of Azopt ophthalmic suspension 1% in the affected eye(s) three times daily. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten (10) minutes apart.
What Drugs, Substances, or Supplements Interact with Azopt?
Azopt may interact with salicylates such as aspirin, Novasal, Doan's Extra Strength, Salflex, Tricosal, and others. Other drugs may interact with Azopt ophthalmic. Tell your doctor all prescription and over-the-counter medications and supplements you use.
Azopt During Pregnancy and Breastfeeding
Azopt should be used only when prescribed during pregnancy. It is unknown if this drug passes into breast milk. Because of the potential risk to the infant, consult your doctor before breastfeeding.
Additional Information
Our Azopt (brinzolamide ophthalmic suspension) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Azopt Consumer Information
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).
Stop using this medicine and call your doctor at once if you have:
eye pain, redness, or swelling;
sensitivity to light;
the feeling of something is in your eye;
stomach pain (upper right side);
jaundice (yellowing of your skin or eyes); or
signs of eye infection--swelling, redness, severe discomfort, crusting or drainage.
Common side effects may include:
blurred vision; or
a bitter or unusual taste in your mouth.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.
In clinical studies of AZOPT® (brinzolamide ophthalmic suspension) 1%, the most frequently reported adverse reactions reported in 5 to 10% of patients were blurred vision and bitter, sour or unusual taste. Adverse reactions occurring in 1 to 5% of patients were blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus and rhinitis.
The following adverse reactions were reported at an incidence below 1%: allergic reactions, alopecia, chest pain, conjunctivitis, diarrhea, diplopia, dizziness, dry mouth, dyspnea, dyspepsia, eye fatigue, hypertonia, keratoconjunctivitis, keratopathy, kidney pain, lid margin crusting or sticky sensation, nausea, pharyngitis, tearing and urticaria.
DRUG INTERACTIONS
Oral Carbonic Anhydrase Inhibitors
There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and AZOPT® (brinzolamide ophthalmic suspension) 1%. The concomitant administration of AZOPT® (brinzolamide ophthalmic suspension) 1% and oral carbonic anhydrase inhibitors is not recommended.
High-Dose Salicylate Therapy
Carbonic anhydrase inhibitors may produce acid-base and electrolyte alterations. These alterations were not reported in the clinical trials with brinzolamide. However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of acidbase alterations have occurred with high-dose salicylate therapy. Therefore, the potential for such drug interactions should be considered in patients receiving AZOPT® (brinzolamide ophthalmic suspension) 1%.
&Copy; Azopt Patient Information is supplied by Cerner Multum, Inc. and Azopt Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
